David Cox is a human guinea pig. He is also a man with a cancer for whom there are no more conventional options and who reasonably believes that, at 56, it is too early to call it a day. So Cox is only too happy to be one of the first people to try out a new drug, fresh from the laboratory. It could come with a load of unpleasant and unexpected side-effects. But it just might save his life.
Cox was diagnosed with mesothelioma three years ago – the result of working as an engineer in a boiler room full of asbestos, he believes. It’s a cancer that doesn’t usually have a good outcome. Like many people with advanced cancers, he has been on one trial after another. The last was a phase 2 – the trial of a drug that has been shown to be safe and have some effect in some people already. It seemed to work for six months, he said, and then it stopped.
“I went for the results of some scans on the Tuesday,” he said. “They told me the results and the options I had. Within three days they’d got me on this trial.” This is a phase 1 trial – a drug that has never been tested in humans before.
Cox didn’t think twice about it. “I had nothing to lose,” he said. When he was warned about possible side-effects, he remarked that the side-effects of not trying another drug were death. “You can’t get much worse than that,” he told his doctor.
Both his trials were run by the Royal Marsden, the world-renowned cancer hospital. The first was at its Chelsea site in west London. The latest is taking place at the other site in Sutton, south London, where the Marsden’s cancer doctors work in close collaboration with scientists at the cutting edge of drug discovery and genomics in the adjoining building belonging to the Institute of Cancer Research.
When Harpal Kumar, chief executive of Cancer Research UK talks of a “golden era” of cancer research, these are some of the scientists and clinicians who are making it happen.
The Marsden uniquely has a drug development unit integrated into the hospital, allowing patients who have run out of options on conventional drugs to join trials where they can get the latest experimental medicines. Where those drugs were once aimed at a single cancer – breast or prostate or lung – these days they are targeted at particular mutations in the cancer. The old drugs worked in only up to a third of patients because each cancer is different. The new drugs aim to have a higher success rate – in a much smaller group of patients tested for the particular mutation.
Sarah Stapleton who runs the unit, said: “The patients have exhausted standard therapies and they are offered the option of a voluntary trial of targeted therapy.”
For the volunteers with advanced cancers, these experimental drugs are their last chance, but Stapleton and the doctors have to be careful what they say to them. “We have to be very honest about what we’re offering to our patients here. There are lots of ethical considerations for a patient entering a trial. These drugs are at a very early stage. They might not help and there is a fairly low chance of helping and they could cause them more problems in terms of side-effects than they are experiencing at the moment.
“The key is explaining it is not a miracle drug. Sometimes that is what people can expect, but it is not what we have got.”
A trial will last two or three years. Patients have to stay in hospital usually for the first month – though they go home at weekends. “It is a huge time commitment because they have to come every week. We are going to take some time that they may not get back,” said Stapleton. But many are philosophical and altruistic. They join the trial in the hope that it may help others, even if not themselves.
The exciting times are when they see particularly good and sometimes even dramatic results. It happened with a drug to prevent cancer returning in women with the BRCA genes that predispose them to breast and ovarian cancer. “We saw very good response rates from that,” said Stapleton.
If Kumar from Cancer Research is right, the unit could be seeing more and more good outcomes. The Marsden is involved in the tumour testing trial that is about to start – supplying patients and also one of the three labs that will design and interpret panels of genetic tests. Somehow, they have to do it within a tight budget – the plan is to find a relatively cheap and feasible way to offer these molecular diagnostic tests across the whole of the NHS.
Dr David Gonzalez de Castro, head of the Marsden’s molecular diagnostics laboratory, said the first two years, involving 9,000 tumour samples from patients in seven hospitals, was a bid to find out whether it was possible. “The question is can the NHS provide molecular diagnosis for all cancer types routinely and can this be linked not only to patient outcome but also research?” he said.
Each genetic test for lung, colorectal or breast cancer costs around £150 to £200. Cancer Research’s plan is to carry out a panel of five or six tests for each cancer type for maybe £300. Gonzalez de Castro shakes his head in a sort of wonder. “It’s a challenge,” he says with a laugh. If all goes well, after two years the tests will begin to be offered in a further 10 to 20 centres. Then before long, the testing will be available throughout the NHS. The government is behind the scheme – it committed to developing and funding a national testing structure in the last cancer plan in January.
The testing is essential even now to find out whether, for instance, a woman with breast cancer is HER2 positive and needs Herceptin or a man with bowel cancer has a K-RAS gene mutation and should be given another cancer drug called cetuximab. Yet, according to a recent study by the Royal College of Pathologists, not everybody who needs a test is getting one.
But the new trial has a second and equally important and exciting purpose beyond securing equal access to tumour testing. All the patients who join will be asked if their results can be stored, along with details of their treatment and the outcomes. Cancer Research will be working with the cancer registries who already collect anonymised data on patients, said James Peach, its director of stratified medicine who is in charge of the project.
It is exciting, says Peach, because researchers will be able to find out what works, not just in terms of drugs but also surgery and radiotherapy, for people with cancers caused by specific genetic mutations. It opens the way to much better, more accurate treatment. “We will find out which drugs we should not be using and discover combinations we did not know about,” he said. There will also be significant benefits in surgery and radiotherapy, because scientists may discover which sorts of tumours are likely to be more aggressive than others.
guardian.co.uk © Guardian News & Media Limited 2010
Your home has a 50% chance of harbouring asbestos, which could be lethal if disturbed.
The use of asbestos has been common in the industrialised world since the mid-19th century and it was not until 1999 that a total ban was imposed. Lee Carter, principal director of the consultants WSP Environment & Energy, says that it has been widely used in residential property: “Among private homes, more than 50% are likely to include some asbestos-containing materials.”
While this may sound alarming, asbestos is likely to be dangerous only if it is released into the air and you breathe it in. Then you could be at long-term risk of developing lung cancer, asbestosis or mesothelioma (a cancer that forms in the lining of the chest or abdomen). Experts say that there should be little or no risk if the asbestos is enclosed and left undisturbed but it must be regularly checked for signs of deterioration.
But accidents happen and the previously dormant devil within could be released when “improvement” work is being carried out, for example, or when a burst pipe causes damage to ceilings.
This is what happened to Brian Fitzpatrick, 49, from South Darenth, Kent, who endured the Christmas from hell when he discovered water damage in his house on 22 December. Pipes had burst in the loft and contractors alerted him to the threat of asbestos in the Artex coating on his ceilings. Before the sample results came back, one of the ceilings collapsed and the industrial dryer blew asbestos around the house. Fitzpatrick and his family have had to relocate while repairs and decontamination take place, a process that could continue for several more months.
Although the results of sampling tests indicated a low number of asbestos particles in the air, the family remain concerned for the future. Fitzpatrick, a partner at the building consultancy EC Harris, said: “It’s a nightmare. No one expected asbestos. Emotionally, the experience has been traumatic for all the family but especially for my wife and daughter.”
Fitzpatrick says that his insurer is picking up the £10,000 cost of replacing all 13 ceilings, as well as the cost of air-quality and material sampling tests, and is paying up to £30,000 for the family’s emergency accommodation. The soft furnishings in the house will have to be disposed of under controlled conditions.
But the Association of British Insurers points out that policies will cover removal of asbestos only as part of a householder’s damage claim, and not simply because asbestos happens to have been identified.
In older homes, asbestos is often present in ceilings decorated using Artex textured coating. This is because, until the mid-1980s, Artex was made with white asbestos to strengthen it. However, Joe Oakins, a surveyor at Vintec Environmental Management, says: “We find asbestos products used in the strangest places and sometimes apparently for no reason. Often builders used whatever they had lying around, so you often find off-cuts of asbestos boards used as packing and filler.”
Peter Coling, technical director at Kinleigh Folkard & Hayward Chartered Surveyors, estimates that 30% of asbestos is found in ceiling coatings, 15% in boiler flue pipes and ducts, and 15% in floor tiles. A further 15% is found in areas such as cold water storage tanks, insulation materials, eaves, gutters and rainwater pipes, while 10% is in cement panel ceilings, 10% in outbuildings and 5% in fire protection materials, for example on the underside of integral garage roofs and in cupboards enclosing boilers.
Phil Wright, chief engineer at the inspection and insurance service Allianz Engineering, says: “It is difficult to establish how much asbestos is present in a home without employing a specialist to undertake a full inspection.” Samples need to be taken for analysis at a laboratory approved by the United Kingdom Accreditation Service.
Debbie Hales, director of Asbestos First, one of 450 licensed removal firms in the UK, says: “With textured coatings you have to take [samples] from different locations. It can be free of asbestos in one part and not in the next because of the way it was manufactured.”
Hales says that the cost of a sampling visit should be about £150 plus VAT. If any additional samples are required during the visit, expect to pay about £20 plus VAT per sample. To remove an area of textured coating, such as Artex, containing asbestos costs about £1,200 plus VAT for up to 20sq m, including disposal and air-quality tests.
guardian.co.uk © Guardian News & Media Limited 2010